CARLA SMITH-RICKS: Open Payments
NPI 1902096746 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,873 in 79 payments from 16 companies in 2025. Trend: 2023 $1,909 · 2024 $1,276 · 2025 $1,873
Food & beverage: $1,873
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 21 | $468 |
| GENZYME CORPORATION | 12 | $372 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $206 |
| Novartis Pharmaceuticals Corporation | 10 | $192 |
| GlaxoSmithKline, LLC. | 10 | $156 |
| ABBVIE INC. | 3 | $84 |
| Optinose US, Inc. | 3 | $69 |
| Regeneron Healthcare Solutions, Inc. | 2 | $62 |
| CSL Behring | 2 | $57 |
| Organon LLC | 3 | $54 |
Products named: DUPIXENT, NEFFY, FASENRA, TEZSPIRE, TRELEGY ELLIPTA, Rhapsido, AIRSUPRA, RINVOQ.
Industry payments across NY — which companies pay providers there.
